Good news: Strain-specific vaccine coming soon, will be helpful in fighting every variant of Corona

The strain-specific vaccine is coming soon to the country. This vaccine is being prepared through the central government. This vaccine will define that is helpful in combating the changing nature of the virus. The vaccine is considered very powerful, especially in protecting against Omicron or others.

The Department of Biotechnology, under the Science Ministry, is working towards creating an eco-system for the rapid development of anti-COVID vaccines, which will primarily target the dominant variant. An official who helped prepare this eco-system to develop a second-generation vaccine spoke to News in Headlines and told us that research and development work is going on to develop a strain-specific vaccine in India.

The official said on the condition of anonymity- ‘Maximum pharmaceutical companies have joined hands with educational institutions for research and development. So that the country can be removed from any new kind of worry.’ The project is demand a joint bringing together of academic institutions, pharmaceutical companies, and manufacturers to develop a bivalent vaccine.

What is a bivalent vaccine?

Current vaccines used in the whole of India and beyond are univalent and polyvalent, it means that these vaccines are designed to target a particular variant of the virus – the original coronavirus. Whereas a bivalent vaccine (bivalent vaccine) will target the particular spike mutation seen in the Omicron strain, which has mutated multiple times to produce sub-variants and second-generation variants. The univalent and divalent vaccine increases immunity as opposed to two different antigens. In that case, it is more important in relation to Omicron. Let us tell you that the fifth variant remains a cause for concern. Due to this, the virus is spreading even more rapidly.

Innovation of strain-specific vaccine

Innovation is being done to develop a proof vaccine for the variant. Serum Institute of India and Bharat Biotech both are already working on a strain-specific vaccine. SII has collaborated with Nonavax. Bharat Biotech organization is working with CEPI for pandemic mobility.

An official said- ‘We expect the second-generation vaccine to deal with this epidemic. Dr. Rajeev Jayadevan, Vice Chairman, IMA Research Cell, Kochi, said in a conversation with News in Headlines that current vaccines protect against serious disease and death, but are not able to prevent infection. In such a situation, now the changed versions of the virus are open out.

fasten protein with strain-specific vaccine

‘All current vaccines are based on the ancestral depression of the virus. Most of them are based on only one part of the virus, which is called the fasten protein. But we have seen in the last two and a half years that the virus is constantly changing its spike protein in an attempt to escape and spread more by the human immune system (human immune response). These changes are also called mutations. These can be done either in a phased manner or in a rapid manner.

He cautioned- ‘Early research about Omicron-based vaccines has not shown a significant benefit on ancestral depression. More variants are being tested, and they have been shown to respond better than the older vaccine. However, we do not have an accurate result of protection, which guarantees a certain level. He also said that there is still a concern about being valid when the next edition of these vaccines arrives. It may or may not have similitude to Omicron.